ALISO VIEJO, Calif. / Dec 23, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the...Read more
Assuming successful validation, the Company currently expects to launch the pipeline test by the end of 2025 FRIENDSWOOD, Texas / Dec 23, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking...Read more
SALT LAKE CITY / Dec 23, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced it has closed its private offering (the “Offering”) of $125 million aggregate principal amount of 7.875% senior secured notes due 2027 (the “notes”) at an offering price of 101.5% of the principal amount thereof, plus accrued interest from and including October 15, 2024. “We are pleased to have successfully closed the offering of...Read more
VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini. As a line extension of the RECELL GO system, the RECELL GO mini disposable...Read more
MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the...Read more
WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the...Read more
Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India. This milestone trial, which has commenced with the successful treatment of five patients with cancerous lymph nodes, represents a transformative step in advancing innovative cancer therapies. This initial trial in India closely aligns...Read more
HOUSTON, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, is pleased to announce the launch of Phase 1 of its proprietary virtual clinic. The virtual clinic will utilize artificial intelligence (AI) and Nexalin’s new Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS). This AI...Read more
LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17),...Read more
In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & gene fusion assays OGM was also more sensitive, including detection of diagnostic or pathogenic variants missed by karyotype in 74% (14/19) of cases that failed or were negative by karyotyping When OGM results and next-generation...Read more
DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that a 14th site is now activated and able to enroll subjects in the NEUTRALIZE-AKI pivotal trial. The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the Company’s proprietary...Read more
Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release dated December 12, 2024, it has closed an over-subscribed, non-brokered private placement of 25,459,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $2,545,900 (the "Offering"). Each Unit consists of one common share of...Read more
NEWTOWN, Pa., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the first PoNS System sale to the VA Healthcare System. The PoNS System sale through our distributor, Lovell Government Services (“Lovell”), was at the contracted price of $23,844,...Read more
WARSAW, Ind., Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The...Read more
State-of-the-art instrument enhances research in structural biology and protein analysis ZÜRICH / Dec 20, 2024 / Business Wire / Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich, and the University of Zürich. This state-of-the-art instrument will significantly enhance the research capabilities...Read more
Unique cell-impermeable1 design extends life-saving treatment for dialysis patients Merit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and...Read more
PALO ALTO, Calif. & TAMPA, Fla. / Dec 20, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. Recognizing the evolving...Read more
Announces early access availability of ProteoVue Software ProteoVue is part of broader set of innovation initiatives, including the Company’s recently announced collaboration with NVIDIA, to leverage AI to enhance sequencing performance BRANFORD, Conn. / Dec 20, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a new paper that was...Read more
SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu." Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the...Read more
Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide. The demand for cancer tissue continues to grow as cancer remains a significant area of focus in medical...Read more
Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning...Read more
SOUTH SAN FRANCISCO / Dec 19, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. Pacific Time in San Francisco, California. The...Read more
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT. A live...Read more
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare...Read more
New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S....Read more
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s...Read more
NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration Study represents the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Dec 19, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company...Read more
BOSTON / Dec 19, 2024 / Business Wire / Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling. In the field of...Read more
Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics’ (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to...Read more
Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first...Read more
Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC...Read more
VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing of new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. Building upon the positive...Read more
Initial patient enrollment anticipated during first quarter of 2025 White Bear Lake, Minnesota--(Newsfile Corp. - December 19, 2024) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company, today announces it has selected seven study sites for participation in its pivotal clinical trial to investigate its fully implanted Acclaim® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to...Read more
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for colorectal...Read more
Completed US$7.7 million financing and reverse takeover to take Company public Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company to fully repay debt to that partner U.S. FDA submission of Novasight 3.0 system on track for calendar 2025 TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”),...Read more
DUBLIN / Dec 18, 2024 / Business Wire / ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and...Read more
MARLBOROUGH, Mass. / Dec 18, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu. H5N1 bird flu, also known as avian influenza A...Read more
DEERFIELD, Ill. / Dec 18, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. José (Joe) E. Almeida, Baxter's chair, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for...Read more
CHICAGO / Dec 18, 2024 / Business Wire / Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreement with Avalon, Tempus is a participating provider...Read more
PALO ALTO, Calif. / Dec 18, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal...Read more
Results published in two articles in Brain Stimulation LONDON / Dec 18, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its effectiveness on...Read more
MENLO PARK, Calif., Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15 at 9:00 a.m. PT. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at...Read more
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference. The...Read more
VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. A live audio webcast of the...Read more
Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis., Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter analysis found that radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), delivered with the CyberKnife®...Read more
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT)...Read more
DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity...Read more
Toronto, Ontario – TheNewswire - December 18, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce Ventripoint and ASCEND Cardiovascular, a leading provider of cardiovascular IT solutions, have signed a term sheet defining the general terms and conditions for a non-exclusive license to Ventripoint’s VMS+ proprietary technology. The two parties expect to execute the...Read more
Initiative Includes Milestone-Based Inventory Purchase Commitments During Q1 and Q2, 2025 Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce the Company has signed a letter of intent (LOI) for a Venowave distribution...Read more
Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial...Read more
LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates...Read more
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for clearance following FDA review of its Intelligent Fingerprinting Drug Screening System (the "System"), an...Read more
Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system The device has received U.S. Food and Drug Administration Breakthrough Device Designation, which expedites the review of innovative technologies By creating a new pacing approach for the left bundle branch area of the heart,...Read more
FRANKLIN LAKES, N.J. and AUSTIN, Texas, Dec. 17, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other...Read more
Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and Gemini models and will initially enhance Stelo’s Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep Proprietary platform lays foundation for future GenAI advancements...Read more
New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C., Dec. 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the commercial availability of its new H5 bird flu molecular test to aid in the diagnosis of human infection with H5 bird flu. The...Read more
SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET. A live and archived webcast of this event, where applicable, will be available by accessing the CooperCompanies’...Read more
WALTHAM, Mass. / Dec 17, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will...Read more
New decision establishes reimbursement for the clinical use of Tempus ECG-AF, reducing the financial burden of using AI to improve early detection of atrial fibrillation CHICAGO / Dec 17, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS)...Read more
LANSING, Mich., Dec. 17, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, has introduced a new addition to its Petrifilm® product line, the Neogen Petrifilm Bacillus cereus Count Plate. This innovative new solution offers food safety professionals a simple, reliable, and efficient method for testing for Bacillus cereus, a persistent threat with potentially deadly consequences. The...Read more
Preclinical data demonstrates advantages of the nano-PFA Cardiac Surgical System over radio frequency technology for ablation of cardiac tissue MIAMI / Dec 17, 2024 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This...Read more
Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business BILLERICA, Mass. / Dec 17, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. (“EMISSION”). Quanterix expects the transaction will close in January...Read more
The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered...Read more
WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The Company also...Read more
Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported...Read more
Toronto, Ontario, December 17, 2024 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that it has closed the first tranche of its previously announced (see November 6, 2024 and December 9, 2024 press releases) amended non-brokered private placement of unsecured convertible debentures (“Debentures”). Ventripoint has issued an aggregate of $341,000 principal amount of Debentures with an...Read more
Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET STONY BROOK, NY / ACCESSWIRE / December 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today...Read more
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.1 It is...Read more
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). LeMaitre also...Read more
BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025....Read more
SALT LAKE CITY / Dec 16, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced it has commenced a private offering (the “Offering”), subject to market and other conditions, of $125 million aggregate principal amount of its 7.875% senior secured notes due October 15, 2027 (the “notes”). The notes offered hereby will be issued as “Additional Notes” and will constitute a further issuance of our 7.875% senior secured...Read more
NEW YORK & BURLINGTON, Mass. / Dec 16, 2024 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 at the Westin St. Francis in San Francisco, California. Joseph DeVivo, President, Chief...Read more
PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants. The MicroQuad™...Read more
Posts Strong Adjusted EBITDA Margin1 for Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2024 financial results and operational highlights....Read more
First cable-free, ambulatory ECG that captures the heart’s electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in...Read more
ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authorization decision expected in Q1, 2025 CAESAREA, Israel, Dec. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"),...Read more
Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the...Read more
FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal first quarter ended October 31, 2024. First Quarter Highlights Enzo ended the first quarter with aggregate cash and cash equivalents of $47.7 million. The net cash used in operating activities during the first quarter decreased by $4.4 million compared to the prior...Read more
WHITE BEAR LAKE, Minnesota , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on providing hearing loss suffers with innovative solutions today announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,151,102 on November 25, 2024. The title of the patent is Combination Hearing Aid and Cochlear Implant System....Read more
AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira’s President Dr. Sandra Milligan will step into the...Read more
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof) one Class A warrant to purchase one...Read more
StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its third quarter financial results for the three and nine...Read more
Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update. Second Fiscal Quarter 2025...Read more
BRISBANE, Australia & EAGAN, Minn. / Dec 16, 2024 / Business Wire / Anteris Technologies Global Corp. (“ATGC” or “Anteris”) is pleased to announce the closing of its initial public offering of 14,800,000 shares of its common stock (the “Common Stock”) in the U.S. at a price of $6.00 per share (the “Offering”). An additional 2,220,000 shares of Common Stock are issuable pursuant to the underwriters’ option to purchase additional shares...Read more
New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement WARSAW, Ind., Dec. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural...Read more
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the...Read more
NSF Recognition: A Testament to Innovation Driving Strategic Growth and Shareholder Value WEST PALM BEACH, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- QHSLab Inc. ("the Company") (OTCQB: USAQ), a leading provider of digital healthcare solutions and diagnostic technologies, is thrilled to announce that it has been invited by the prestigious National Science Foundation (NSF) to submit a full Phase I application for the development of...Read more
Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its Next Day Quote Program ("NDQ"). This next-day quote service for researchers and providers is tailored to accelerate the...Read more
SAGITTARIUS is Natera's first interventional trial using SignateraTM to select patients for targeted therapy in early-stage colon cancer Approximately 700-900 patients expected to be enrolled across more than 20 sites AUSTIN, Texas / Dec 12, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial....Read more
Ingenuity Pathway Analysis Interpret extends analysis capabilities of human-curated knowledge base with AI technology AI-extension highlights key biological elements at work and provides summarized results and interpretations in a sharable web document, speeding up interpretation Ingenuity Pathway Analysis Interpret unlocks the full potential of biological data by streamlining interpretation process and delivering actionable insights...Read more
| Company | Change | Last Trade |
|---|---|---|
| Mettler-Toledo | 3.65 0.30 | $1,234.39 |
| Intuitive Surgical | 2.79 0.53 | $527.22 |
| ICON | 2.51 1.21 | $210.02 |
| Movano Health | 2.48 79.74 | $5.60 |
| electroCore | 2.25 14.73 | $17.52 |
| Establishment Labs | 2.13 5.32 | $42.14 |
| Abbott | 1.89 1.68 | $114.31 |
| Stryker | 1.89 0.52 | $366.49 |
| IQVIA | 1.84 0.93 | $199.11 |
| Medpace | 1.77 0.52 | $339.05 |
| Haemonetics | 1.74 2.31 | $77.18 |
| Lantheus | 1.73 1.94 | $91.01 |
| Sonendo | 1.62 704.35 | $1.85 |
| Waters | 1.60 0.43 | $369.76 |
| Axogen | 1.55 9.91 | $17.19 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE